And

are now a part of the new and improved

Advertisement

Dermwire News

News | April 15, 2019

A Conserved Stress Response May Fuel Resistance to BRAF Inhibitors in Melanoma

Moffitt Cancer Center researchers have discovered a mechanism by which melanoma cells become resistant to drugs that target the BRAF protein and its signaling pathway. Their study was published online in the journal Cancer...

Read More

News | April 16, 2019

Maine Gets SUNucated

Maine is joining 19 other states in allowing students to possess and use sunscreen in school. Governor Janet Mills signed LD 441, which was sponsored by Senator Cathy Breen. Modeled after American Society for Dermatologic Surgery...

Read More

News | April 16, 2019

Industry Vet Linda Esposito Named New CFO at Skyn ICELAND

Linda Esposito is the new Chief Financial Officer at Skyn ICELAND, a privately held New York-based skin care company. Ms. Esposito will report to Founder and Chief Executive Officer Sarah Kugelman and will oversee all financial...

Read More

News | March 28, 2019

PALLAS Ti: Sapphire Solid State Laser Shows Similar Efficacy and Safety to 308nm Excimer Laser for Localized Vitiligo

A novel 311nm Titanium:Sapphire UV laser demonstrates comparable efficacy and safety when compared to 308nm excimer laser in the treatment of localized vitiligo, according to a study recently published in Lasers in Surgery and...

Read More

News | April 3, 2019

PellePharm: Phase 3 Trials for Patidegib for Gorlin Syndrome Underway

PellePharm, Inc., has dosed the first patient in a pivotal Phase 3 clinical trial of Patidegib Topical Gel, 2%, vs. vehicle gel in patients with Gorlin Syndrome. The Phase 3 study is intended to assess the safety and efficacy of patidegib...

Read More

Advertisement

The Latest News

Advertisement

View more

Advertisement